Enzyme Therapy: Current Challenges and Future Perspectives
dc.contributor.author | De la Fuente López, Miguel | |
dc.contributor.author | Lombardero, Laura | |
dc.contributor.author | Gómez-González, Alfonso | |
dc.contributor.author | Solari, Cristina | |
dc.contributor.author | Angulo Barturen, Iñigo | |
dc.contributor.author | Acera Osa, Arantxa | |
dc.contributor.author | Vecino Cordero, Elena | |
dc.contributor.author | Astigarraga, Egoitz | |
dc.contributor.author | Barreda Gómez, Gabriel | |
dc.date.accessioned | 2021-09-16T09:36:06Z | |
dc.date.available | 2021-09-16T09:36:06Z | |
dc.date.issued | 2021-08-25 | |
dc.identifier.citation | International Journal of Molecular Sciences 22(17) : (2021) // Article ID 9181 | es_ES |
dc.identifier.issn | 1422-0067 | |
dc.identifier.uri | http://hdl.handle.net/10810/53101 | |
dc.description.abstract | In recent years, enzymes have risen as promising therapeutic tools for different pathologies, from metabolic deficiencies, such as fibrosis conditions, ocular pathologies or joint problems, to cancer or cardiovascular diseases. Treatments based on the catalytic activity of enzymes are able to convert a wide range of target molecules to restore the correct physiological metabolism. These treatments present several advantages compared to established therapeutic approaches thanks to their affinity and specificity properties. However, enzymes present some challenges, such as short in vivo half-life, lack of targeted action and, in particular, patient immune system reaction against the enzyme. For this reason, it is important to monitor serum immune response during treatment. This can be achieved by conventional techniques (ELISA) but also by new promising tools such as microarrays. These assays have gained popularity due to their high-throughput analysis capacity, their simplicity, and their potential to monitor the immune response of patients during enzyme therapies. In this growing field, research is still ongoing to solve current health problems such as COVID-19. Currently, promising therapeutic alternatives using the angiotensin-converting enzyme 2 (ACE2) are being studied to treat COVID-19. | es_ES |
dc.description.sponsorship | This research was funded by the Basque Government, BIKAINTEK, grant number 48-AF-W2-2019-00006; and by University of the Basque Country, PIFIND19/02, grant number 201900016247. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | |
dc.subject | biotechnology | es_ES |
dc.subject | enzyme therapy | es_ES |
dc.subject | encapsulation | es_ES |
dc.subject | molecular modification of enzymes | es_ES |
dc.subject | monitoring of immune response | es_ES |
dc.subject | microarray | es_ES |
dc.subject | COVID-19 | es_ES |
dc.title | Enzyme Therapy: Current Challenges and Future Perspectives | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.date.updated | 2021-09-09T13:47:08Z | |
dc.rights.holder | 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). | es_ES |
dc.relation.publisherversion | https://www.mdpi.com/1422-0067/22/17/9181/htm | es_ES |
dc.identifier.doi | 10.3390/ijms22179181 | |
dc.departamentoes | Biología celular e histología | |
dc.departamentoeu | Zelulen biologia eta histologia |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).